michaelmurphy234, you should read Psycho Analyst's recent articles on Seeking Alpha in which she talks about Bydureon's dangers to your health. If you are not concerned about your diabetic health relative to $15 extra per month, no one cares but you.
centralcoastinvestor, Al let us know the $50 million milestone was to meet the Afrezza volume availability for product launch by January 23. He said MNKD met the milestone two weeks early. Al also said the yields of Afrezza were better than forecast.
It is in Maryland, and I would like to know if anyone on this board was there or communicated with someone who heard him speak. Besides Al Mann I know Afrezza will be discussed on some of the panels, because Dr. Klonoff, a leader on some of the panels, has written favorable information on Afrezza in the November issue of the Journal of Diabetes Science and Technology that is on the web.
mikesmilitaria, I have tried to get doctor.stockpicker's attention on the problems of his prescribing Metformin, but I have never gotten any replies from him. I share your concerns about Metformin, but doctors appear to prescribe it all the time to Type 2 diabetics. That practice should stop I hope with Afrezza's availability. I lifted your Metformin post below. Maybe you can get doctor stockpicker's attention.
"That one pill per day, like Metformin is poison.
The RX of which you speak forces the body to "circumvent excess sugar" and pass it thru the kindeys and out via urination. Now if sugar(diabetes) destroys your organs and now with that one pill a day, you put the kidneys thru handling excess sugar, day in, day out, what ultimate effect will that process have on your kidneys? That is one of the box warnings on the one pill per day.
Afrezza is natural human MONOMERIC insulin that has a therapy profile identical to that of the pancreus.
It has NO adverse side effects and "balances the body's sugar" the way nature intended.
Metformin takes the pancreus and forces/squezzes the organ to produce insulin so you in fact, take a weak, barely functioning organ and wear it out, pushing you to T1 diabetes from T2."
I noticed uncharacteristic posts, and then I noticed redhaw_20000 (redhaw twenty thousand) is trying to impersonate redhaw_2000.
sellhighdrinklow, you are clearly not a type 1 diabetic. There is a time line involved. Go back and review your readings. Also afrezzauser stated he has his Dexcom set to alert at 150. If you still represent yourself as a diabetic, get yourself an Afrezza prescription and enjoy the benefits. It will answer your questions.
lakers_w, this is the first article I can remember in which Orelli has said positive things about MNKD. Frankly without his saying he has modified his stance on Afrezza and MNKD, it appears he is thinking more positively about MNKD after hearing the latest November 3 MNKD conference call. There is no getting away from the position that Orelli has likely changed his mind enough about MNKD to start thinking with a somewhat more open mind about the company and Afrezza. I notice, however, he did not mention that MNKD said Afrezza will have a prominent place in the Sanofi November 20th presentation on Sanofi's new products it will be introducing soon.
winwina88, Sanofi will drop the news on you like the Swiss Central Bank dropped the Swiss Franc news today.
funkyfreshfee, you may not be paying 22% to be short MNKD, but you are paying a stiff interest rate to your broker. Even if you shorted at $9+, your borrowing charge to remain short has risen a lot in the past few months. I see FIDO is charging 18.75% per annum, which is up about 2% more in the past 30 days. Oh and that is a yearly rate, but your broker is raking your account every month.
google Sticking Point: Sanofi’s Diabetes Franchise Is Crucial to Sorting Out a Mess to see how critical Afrezza is to Sanofi's diabetes success. It is critical . Also the remarks by the WSJ article writer indicates no understanding of diabetes or how insulin works in the body. The only thing these people seem to understand is inhalation, and that severely limits their ability to communicate helpful information to lay people and even diabetics.
afrezzauser, my comments are to make the same suggestion to you that I made to a poster, doctor.stockpicker, who posted he is a doctor in Oklahoma who takes care of a lot of diabetics. I have never gotten a response from this doctor. My suggestion (and I do not think it is unique) is for type 2 diabetics who are not on any diabetes drug, or are on metformin to begin on Afrezza alone at meal times to dampen the blood glucose excursions and possibly (likely) bring the a1c into an acceptable lower range over time. Yes, I mean discontinue the metformin, which is primarily acting on the liver to reduce the steady state level of glucose. The Afrezza, acting as real insulin, will chemically message the liver to reduce the glucose output during meal time digestion periods.
At least start on this procedure to verify blood glucose level improvements before putting type 2 diabetics on a harsh side effect drug like metformin to bring down glucose output from the liver, or even an injected insulin analog like lantus. I am hopeful that a lot of these research labs and research hospitals will run some of these type of trials with Afrezza and report their results at the many diabetes conventions.
meifud, many, many analysts said tablet computers (tablets) would not sell. Especially after several examples in the market showed them. Then the market got a tablet that did what it wanted, and the analysts had to return to their sales forecasts and move them up a lot. They forgot the maxim that they mention all the time. That is past performance does not guarantee future results. You may be called upon to adjust your analyst horizons soon too, but you can cite the analysts for any misfortune.
thanksfather1, it looks like my post was deleted, because I inserted some url information. Search twitter for @kellyclose and not @kelly close. The instagram video is nice. It shows afrezzauser loading and inhaling a mealtime dose of afrezza. From loading to finishing inhaling only took him 5 seconds, and I know because I timed it. Kelly Close is the editor diatribe, a diabetic topic magazine.
I am all for Ken Kam's doing what he does on Forbes, but you should know he appears to work for Marketocracy's Masters, the same business Nate Pile works for. I am hoping Nate Pile is going to help move up MNKD's stock price and hasten a short squeeze with the good information he will receive from diabetics who use Afrezza. He's a smart guy, and will be able to know the difference between shorts or other bogus inputs to him. I am sure he or his people will contact some or all of these people if they have interesting inputs about Afrezza.
Google diabetes technology conference 2014 al mann , and the first link is a pdf of the agenda. The entire conference has a lot of good speakers and panel discussions with Al Mann as a keynote speaker. I noticed that Dr. Klonoff, who is a big supporter of Afrezza in his DST Journal of Diabetes Science and Technology in the current November issue, is a panel leader of several panels at the conference. This will be November 6 and 7.
afrezzauser, I have some comments on this to add to your inputs, but I don't have time for a full reply right now. I will give you a complete reply in the next day or two to this particular thread you have started.
Matt Pfeffer, a bone head, is a total goof at presenting, and Hakan Edstrom is a partial goof when he presents. Al Mann needs to be the only presenter at the conference for MNKD, because he can do the job and do it well. If Al is not doing the presenting, then MNKD should cancel.